Omalizumab allergic reaction

Omalizumab (Xolair) is the first biological drug approved for the treatment of asthma. Omalizumab is a recombinant humanized monoclonal antibody targeted against IgE. IgE bound to omalizumab cannot bind to IgE receptors on mast cells and basophils, thereby preventing the allergic reaction at a very early step in the process. 

MH, Townley RG. Mokhtarani M. Seyfert-Margohs V, Asare A. Bateman K. Deniz Y Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006 117 134-140. 

In a placebo-controUed study of subcutaneous omalizumab (50,150, and 300 mg before the ragweed season and every 3 or 4 weeks during the pollen season) in 536 patients with seasonal allergic rhinitis, injection site reactions were mild and infrequent, there were no clinically significant alterations in laboratory values, and anti-idiotypic antibodies to omalizumab were not detected there was no evidence of immune complex-related adverse events (5-7). 

---